147 related articles for article (PubMed ID: 2151271)
1. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
[TBL] [Abstract][Full Text] [Related]
2. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
3. A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.
Dijkman GA; del Moral PF; Plasman JW; Kums JJ; Delaere KP; Debruyne FM; Hutchinson FJ; Furr BJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):933-6. PubMed ID: 2149507
[TBL] [Abstract][Full Text] [Related]
4. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
[TBL] [Abstract][Full Text] [Related]
6. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
7. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
[TBL] [Abstract][Full Text] [Related]
8. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
[TBL] [Abstract][Full Text] [Related]
9. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer.
Perren TJ; Clayton RN; Blackledge G; Bailey LC; Holder G; Lynch SS; Arkell DG; Cottam J; Farrar D; Young CH
Cancer Chemother Pharmacol; 1986; 18(1):39-43. PubMed ID: 2944668
[TBL] [Abstract][Full Text] [Related]
12. A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group.
Dijkman GA; Debruyne FM; Fernandez del Moral P; Plasman JW; Hoefakker JW; Idema JG; Sykes M
Eur Urol; 1995; 27(1):43-6. PubMed ID: 7744141
[TBL] [Abstract][Full Text] [Related]
13. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
Murphy GP; Greco JM; Chin JL; Huben RP; Scott M; deHaan HA
Urology; 1987 Feb; 29(2):185-90. PubMed ID: 2949417
[TBL] [Abstract][Full Text] [Related]
14. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
15. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
Denis L; Keuppens F; Mahler C; Debruyne FM; Weil EH; Lunglmayr G; Newling D; Robinson MR; Richards B; Smith PH
Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852
[No Abstract] [Full Text] [Related]
16. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
Geldof AA; de Voogt HJ; Rao BR
Prostate; 1987; 11(3):281-90. PubMed ID: 2960958
[TBL] [Abstract][Full Text] [Related]
17. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
Grant JB; Ahmed SR; Shalet SM; Costello CB; Howell A; Blacklock NJ
Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356
[TBL] [Abstract][Full Text] [Related]
18. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
[TBL] [Abstract][Full Text] [Related]
19. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
[TBL] [Abstract][Full Text] [Related]
20. Zoladex treatment of symptomatic prostatic carcinoma.
Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; Knox BS
Am J Clin Oncol; 1988; 11 Suppl 2():S123-6. PubMed ID: 2977267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
